Akero Therapeutics’ Post

🌟 NEW EPISODE ALERT 🌟 Dive deep into the world of Idiopathic Pulmonary Fibrosis (IPF) with Dr. Victor Thannickal on our latest episode of BIO from the BAYOU. 🎙️ Learn about the symptoms, progression, and the groundbreaking drug therapies being developed to combat this devastating lung disease. 🔍 Highlights: • Understanding IPF fundamentals • Impact on patient lives • Innovative therapies from Dr. Thannickal’s lab • Latest research advancements 📲 Listen now and stay ahead in biotech developments! #Biotech #HealthcareInnovation #IPF #LungDisease #PharmaceuticalResearch ➡️ Listen to Episode 36 Now (link in comments)

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma https://ow.ly/WzBu50QhogK

#HappeningNow: In partnership with Incyte, we’re presenting the full results from our AGAVE-201 pivotal trial of axatilimab in patients with chronic GVHD during American Society of Hematology’s #ASH23 Plenary Scientific Session.   We believe that the additional positive data from AGAVE-201 further strengthen axatilimab’s strong safety and efficacy profile as a well-differentiated treatment option for patients with refractory chronic GVHD.   Read the full press release and view the additional data here:  https://bit.ly/3RBczCQ

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Take a look at the re-vamped fibrosis page on PhenoVista's website here! https://hubs.ly/Q02sYTf20 There's a general overview of our capabilities in this disease area and a case study of a completed client project. If you don't find what you're looking for or want to discuss challenges you're facing in fibrosis R&D, shoot let's chat!

The TIGRIS clinical trial is a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion #PMX in a randomized controlled trial of adults treated for endotoxemia and septic shock. The trial methods are detailed in “Bayesian methods: a potential path forward for sepsis trials”. https://lnkd.in/g8zcUzub

🌟 Research Update! 🌟 The #QUILT trial analyzed the effects of the IL-15RαFc superagonist #nogapendekin alfa #inbakicept plus #BCG on patients with BCG-unresponsive #NMIBC. Learn more:

My PhD thesis work focused on studying the impact of bacterial functional amyloids, like CsgA, in Parkinson's disease causation. Extremely delighted to see that novel therapeutics are being developed to target the gut-brain-axis in neurodegenarative diseases. #gutmicrobiome #gutbrainaxis #neurodegeneration #parkinsonsdisease #alzheimersdisease

Dive into the power of QSP modeling next week with Michelle Przedborski, PhD, and Saheli Sarkar, PhD! In this webinar they will discuss how we developed a QSP model to mechanistically link the drug exposure profile to the pharmacodynamic effects for Atacicept and ALPN-303 for the treatment of autoimmune disease. Learn more and register at: https://lnkd.in/eYkBdxNc Date: Thursday, March 21st Time: 12pm - 1pm EST #qsp #mathematicalmodeling #biosimulation #autoimmunedisease

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH: -- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median progression free survival by Kaplan-Meier is 28 months -- -- Oral presentation at ASH will...